Leerink Partnrs Analysts Boost Earnings Estimates for XOMA

XOMA Co. (NASDAQ:XOMA) – Investment analysts at Leerink Partnrs increased their Q2 2025 earnings per share estimates for XOMA in a report released on Thursday, May 15th. Leerink Partnrs analyst D. Risinger now expects that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.22). The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at $0.10 EPS, FY2027 earnings at $1.55 EPS, FY2028 earnings at $3.89 EPS and FY2029 earnings at $6.02 EPS.

Several other analysts also recently commented on XOMA. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Friday, April 11th. Benchmark started coverage on XOMA in a report on Thursday, April 17th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $104.00 price objective on shares of XOMA in a report on Friday, March 28th.

XOMA Price Performance

XOMA stock opened at $27.48 on Monday. The stock has a market capitalization of $328.47 million, a price-to-earnings ratio of -7.90 and a beta of 0.89. XOMA has a 52-week low of $18.35 and a 52-week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock’s 50 day moving average price is $22.13 and its two-hundred day moving average price is $25.38.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.32. The business had revenue of $15.91 million for the quarter, compared to analysts’ expectations of $6.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in XOMA. Woodline Partners LP raised its position in shares of XOMA by 7.9% in the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock worth $3,359,000 after buying an additional 12,284 shares in the last quarter. Stonepine Capital Management LLC increased its stake in XOMA by 3.3% in the 1st quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company’s stock worth $2,587,000 after acquiring an additional 4,113 shares during the last quarter. Eversept Partners LP raised its holdings in shares of XOMA by 1.2% in the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after acquiring an additional 1,128 shares in the last quarter. Northern Trust Corp boosted its position in shares of XOMA by 1.5% during the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after acquiring an additional 1,340 shares during the last quarter. Finally, CM Management LLC boosted its position in shares of XOMA by 16.4% during the 1st quarter. CM Management LLC now owns 64,000 shares of the biotechnology company’s stock valued at $1,276,000 after acquiring an additional 9,000 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

Insider Activity at XOMA

In other XOMA news, CIO Bradley Sitko bought 4,134 shares of the business’s stock in a transaction on Friday, March 21st. The stock was purchased at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the completion of the transaction, the executive now directly owns 10,484 shares of the company’s stock, valued at $250,462.76. This trade represents a 65.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Joseph M. Limber purchased 5,243 shares of the stock in a transaction dated Monday, April 7th. The stock was acquired at an average cost of $25.60 per share, for a total transaction of $134,220.80. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $256,000. This trade represents a 110.22% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 29,312 shares of company stock valued at $735,061. 9.10% of the stock is owned by insiders.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.